New framework identifies 108 lysosomal disorders, nearly doubling recognized conditions
· Medical Xpressedited by Lisa Lock, reviewed by Andrew Zinin
Lisa Lock
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
Lysosomal disorders can have devastating effects on patients but findings from a University of Sheffield-led collaborative study could support more precise diagnosis and help researchers identify shared targets for future treatments. The scientists have brought together the most comprehensive picture yet of rare metabolic disorders, identifying 108 conditions—almost double those originally understood to exist—bringing new hope for early diagnosis and new treatments.
People living with lysosomal disorders can endure a range of symptoms, such as kidney problems, severe muscle weakness, and progressive and fatal damage to the nervous system, depending on their diagnosis.
Lysosomes are specialized structures within cells that break down and recycle cellular material. Traditionally, lysosomal disorders have largely been understood as conditions in which deficiencies of lysosomal enzymes or related proteins lead to the accumulation of "storage" material within cells.
However, advances in cell biology have revealed that lysosomes do much more than dispose of cellular waste. They are involved in processes including cellular signaling, nutrient sensing, membrane trafficking, autophagy (the process by which cells recycle their own components) and communication between different structures within cells.
A broader view of disease
Established science classified only 70 conditions as lysosomal disorders. But a pioneering study involving researchers at the University of Sheffield and across the country has now uncovered 108 disorders, including those not caused by enzyme deficiencies, for the first time.
Published in the Journal of Inherited Metabolic Disease (JIMD), the study presents a new classification encompassing inherited disorders in which disruption of these wider lysosomal functions contributes significantly to disease.
After evaluating disorders against predefined criteria, the researchers classified 108 conditions caused by defects in 102 genes across 11 categories. The analysis also highlighted the complex and frequently multisystem nature of these disorders.
The findings show that these diseases reach far beyond a single area of the body. Roughly 80% of patients experienced brain and nerve issues, and 68% experienced eye complications. Digestive, bone and blood-related issues were also common.
Shared pathways for treatment
Dr. Eamon McCarron, lead author of the study, honorary senior lecturer at the University of Sheffield's School of Medicine and Population Health and consultant and clinical lead in adult inherited metabolic disorders at the Sheffield Adult Metabolic Service, said, "Lysosomal disorders are individually rare, but their effects can be debilitating and, in some cases, life-limiting.
"Our understanding of the lysosome has changed enormously. We now know that it is not simply the cell's waste-disposal system, and lysosomal disease cannot always be understood solely in terms of an enzyme deficiency and the accumulation of material within cells.
"By bringing together 108 inherited disorders within a framework based on modern lysosomal biology, we hope to provide a clearer way of understanding how these diseases relate to one another.
"This could support more precise diagnosis and genetic interpretation and, in the longer term, help researchers identify shared disease mechanisms that could become targets for new treatments. It may also help inform the future development of newborn screening strategies and clinical trials."
The researchers say grouping diseases according to shared biological mechanisms could help identify groups of patients who may benefit from therapies targeting common disease pathways.
This could be particularly important for ultra-rare conditions, where conventional clinical trials evaluating treatments for individual disorders can be difficult.
The study was led by McCarron at the University of Sheffield and Dr. Karolina Stepien, consultant in adult inherited metabolic diseases at Salford Royal Hospital, and brought together expertise from institutions across the U.K. and internationally, including the University of Oxford, University College London and the University of Manchester, alongside international experts from University Children's Hospital Zürich in Switzerland, Leiden University in the Netherlands, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the U.S. National Institutes of Health.
More information
Eamon P. McCarron et al, A Contemporary Pathomechanistic Nosology of Inherited Lysosomal Disorders, Journal of Inherited Metabolic Disease (2026). DOI: 10.1002/jimd.70245
Key medical concepts
Clinical categories
Clinical genetics Provided by University of Sheffield Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New framework identifies 108 lysosomal disorders, nearly doubling recognized conditions (2026, September 14) retrieved 14 September 2026 from https://medicalxpress.com/news/2026-09-framework-lysosomal-disorders-conditions.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.